Communicating Clinical Trial Results: a Not So Bitter Pill to Swallow

After an FDA panel recently recommended that Vioxx could return to the marketplace, investors pushed Merck's stock up 13%. The reason for investor optimism is that this recommendation may limit Merck's legal liability, estimated at as much as $20 billion.